[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 524
Citations 0
February 27, 2018

Errors in Text and Supplement

JAMA. 2018;319(8):833. doi:10.1001/jama.2017.21113

In the Original Investigation entitled “Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation”1 published in the October 3, 2017, issue of JAMA, the incorrect mechanism of action for 2 drugs, rifampin and phenytoin, was reported in the text and Supplement. In the Methods, the final sentence under Follow-up Time and Person-Quarters should read: “These medications were selected because they were P-glycoprotein competitors (digoxin, verapamil, diltiazem, amiodarone, and cyclosporine), CYP3A4 inhibitors (fluconazole and ketoconazole, itraconazole, voriconazole, or posaconazole), or both (atorvastatin, erythromycin or clarithromycin, dronedarone) or CYP3A4 inducer (rifampin and phenytoin), which may have a potential drug-drug interaction with NOACs.” In the Results, the first sentence in the final paragraph under Sensitivity and Additional Analyses should read: “In the third additional analysis, 12 concurrent medications were categorized into 2 metabolic pathway groups: P-glycoprotein competitors group (digoxin, verapamil, diltiazem, amiodarone, and cyclosporine) and both P-glycoprotein competitors and CYP3A4 inhibitors group (atorvastatin; fluconazole; ketoconazole, itraconazole, voriconazole, or posaconazole; erythromycin or clarithromycin; and dronedarone).” Additionally, the footnote in eTable 7 of the Supplement should read: “P, C: Atorvastatin, Fluconazole, Ketoconazole, Itraconazole, Voriconazole, Posaconazole, Clarithromycin, Erythromycin, Dronedarone, P: Digoxin, Verapamil, Diltiazem, Amiodarone, Cyclosporin.” This article was corrected online.

Chang  SH, Chou  IJ, Yeh  YH,  et al.  Association between use of non–vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation.  JAMA. 2017;318(13):1250-1259.PubMedGoogle ScholarCrossref